Sign inSign up
Sign upSign in

GLP-1 Clinical Trials

Registered trials for the GLP-1 and metabolic compounds we track — semaglutide, tirzepatide, retatrutide, and more — pulled from ClinicalTrials.gov and tagged to each compound. 165 of 291 are currently active.

v1.0 · Updated 2026-10-15 · Source: ClinicalTrials.gov API v2 · 291 rows

Download CSVView JSONBrowse the directory
TrialCompoundsPhaseStatusEnroll.Start
Tirzepatide for the Treatment of Cannabis Use DisorderNCT07265752TirzepatidePhase 2Not yet recruiting62027-03-01
Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese PatientsNCT07847515Tirzepatide—Not yet recruiting802027-02-01
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant AccessNCT07858331SemaglutidePhase 4Not yet recruiting8802027-01-01
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryNCT07787936Liraglutide, Dulaglutide—Not yet recruiting1502027-01-01
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNCT07078838TirzepatidePhase 2Not yet recruiting402027-01
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNCT07790861OrforglipronPhase 3Not yet recruiting1922026-12
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT07855900Semaglutide, TirzepatidePhase 3Not yet recruiting3502026-11-07
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNCT07866066SemaglutidePhase 3Not yet recruiting13002026-11-02
Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sNCT07832084Semaglutide, TirzepatidePhase 4Not yet recruiting602026-11-01
Metabolic Surgery for Atrial Fibrillation EliminationNCT07027969Liraglutide, DulaglutidePhase 4Not yet recruiting1002026-11-01
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNCT07729332OrforglipronPhase 4Not yet recruiting602026-11-01
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)NCT07099742Tirzepatide—Not yet recruiting3642026-11
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way ForwardNCT06977438SemaglutidePhase 4Not yet recruiting10202026-10-15
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationNCT07868354TirzepatidePhase 1Not yet recruiting602026-10-08
FutureShape FamilyNCT07872904SemaglutidePhase 4Not yet recruiting4002026-10-01
Danish Trial of Weight Loss to Reduce Atrial Fibrillation ProgressionNCT07816744Semaglutide—Not yet recruiting4802026-10-01
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityNCT07845500TirzepatidePhase 3Not yet recruiting6602026-10-01
Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness TrialNCT07846865TirzepatidePhase 2/Phase 3Not yet recruiting2562026-10-01
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderNCT07825857TirzepatidePhase 2Not yet recruiting2282026-10-01
Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma LocalizationNCT07808879Exenatide—Recruiting202026-10-01
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesNCT07739537OrforglipronPhase 4Not yet recruiting1002026-10-01
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)NCT07859150SemaglutidePhase 4Not yet recruiting1042026-10
Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric SurgeryNCT07859189SemaglutidePhase 4Not yet recruiting1002026-10
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNCT07859176SemaglutidePhase 4Not yet recruiting1002026-10
Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or HigherNCT07859137SemaglutidePhase 4Not yet recruiting1002026-10
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight GainNCT07859163SemaglutidePhase 4Not yet recruiting1002026-10
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusNCT07677891DulaglutidePhase 2Not yet recruiting602026-10
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationNCT07855133SemaglutidePhase 1Not yet recruiting602026-09-30
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)NCT07817875TirzepatidePhase 3Recruiting1502026-09-25
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World StudyNCT07846956Tirzepatide—Not yet recruiting282026-09-21
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNCT07734792TirzepatidePhase 2/Phase 3Not yet recruiting7262026-09-20
A Study of BGM0504 in Early T2DM With ObesityNCT07743983SemaglutidePhase 3Recruiting3722026-09-17
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the EndometriumNCT06073184SemaglutidePhase 2Recruiting712026-09-17
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251CagrilintidePhase 3Recruiting2102026-09-16
Tirzepatide for Treatment of CCCANCT07734870TirzepatidePhase 2Recruiting202026-09-15
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or ObesityNCT07803744TirzepatidePhase 1Recruiting182026-09-11
IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsNCT07793019OrforglipronPhase 1Recruiting1042026-09-07
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336Dulaglutide, OrforglipronPhase 3Not yet recruiting1702026-09
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal DiseaseNCT07478653Semaglutide—Recruiting502026-08-31
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightNCT07842640TirzepatidePhase 1Recruiting842026-08-27
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740CagrilintidePhase 2Withdrawn02026-08-27
A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating SpectrumNCT07870538SemaglutidePhase 4Recruiting962026-08-26
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579OrforglipronPhase 3Recruiting20012026-08-26
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613CagrilintidePhase 3Recruiting802026-08-04
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightNCT07745504CagrilintidePhase 3Recruiting2852026-08-04
Imaging in Semaglutide StudyNCT07695454Semaglutide—Recruiting102026-07-30
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307OrforglipronPhase 3Recruiting1302026-07-15
Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 DiabetesNCT07835360Tirzepatide—Recruiting2002026-07-10
Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative StudyNCT07866183Tirzepatide—Recruiting1202026-06-29
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388SemaglutidePhase 2Recruiting3002026-06-22
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766CagrilintidePhase 3Withdrawn02026-06-22
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsNCT07702461Liraglutide, Dulaglutide, Exenatide—Recruiting3002026-06-12
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral SclerosisNCT06726577LiraglutidePhase 1/Phase 2Recruiting602026-06-04
GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without DiabetesNCT07858864Semaglutide, Tirzepatide—Recruiting422026-05-30
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587CagrilintidePhase 1Recruiting1142026-05-29
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910TirzepatidePhase 2Recruiting2042026-05-22
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414CagrilintidePhase 3Recruiting25002026-05-21
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)NCT07559500TirzepatidePhase 1Recruiting1762026-05-20
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052CagrilintidePhase 1Completed502026-05-20
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018CagrilintidePhase 1Recruiting2342026-05-18
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.NCT07301437LiraglutidePhase 4Not yet recruiting1202026-05-01
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088DulaglutidePhase 4Not yet recruiting4682026-05
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953CagrilintidePhase 1Recruiting1202026-04-30
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisNCT07497399ExenatidePhase 2Recruiting1202026-04-28
Tirzepatide in Obesity-Driven Endometrial CancerNCT07065552TirzepatideEARLY_Phase 1Recruiting202026-04-27
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195CagrilintidePhase 1Recruiting1002026-04-10
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)NCT07547878SemaglutidePhase 4Enrolling by invitation642026-04-08
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityNCT07218445TirzepatidePhase 4Recruiting402026-04-08
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaNCT07107334Liraglutide, OrforglipronPhase 2Recruiting202026-04-07
A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846TirzepatidePhase 1/Phase 2Recruiting1562026-03-02
Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKDNCT07187830Semaglutide—Recruiting522026-02-23
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic OutcomesNCT07424430Semaglutide—Completed33922026-02-20
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447RetatrutidePhase 2Recruiting3002026-02-15
The Evira Study: Additional Support During Obesity TreatmentNCT06836284Liraglutide—Recruiting402026-02-13
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560CagrilintidePhase 1Recruiting1002026-02-09
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.NCT07417631Dulaglutide—Completed3000002026-02-03
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)NCT07417618Dulaglutide—Completed600002026-01-27
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415RetatrutidePhase 3Active not recruiting6002026-01-24
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskNCT07619495Dulaglutide—Completed1200002026-01-20
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusNCT07347080ExenatideEARLY_Phase 1Recruiting92026-01-20
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285CagrilintidePhase 3Recruiting4602026-01-08
Estimating the Impact of Obesity Medications on Clinical and Economic OutcomesNCT07640139Liraglutide—Enrolling by invitation1250002026-01-01
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesNCT07284979SemaglutidePhase 3Active not recruiting12702025-12-30
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813DulaglutidePhase 1Completed202025-12-29
Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisNCT07282041DulaglutidePhase 2/Phase 3Recruiting1302025-12-17
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric RetentionNCT07276763Dulaglutide—Not yet recruiting165092025-12-10
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390OrforglipronPhase 3Recruiting71402025-12-01
ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy AgingNCT07871799SemaglutidePhase 2Completed312025-11-17
A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719RetatrutidePhase 3Active not recruiting2502025-11-17
Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesNCT07834398DulaglutidePhase 3Completed1502025-11-14
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816LiraglutidePhase 1Recruiting712025-11-07
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759CagrilintidePhase 3Active not recruiting3302025-11-05
Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642CagrilintidePhase 3Active not recruiting3002025-11-05
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593OrforglipronPhase 3Recruiting12052025-10-31
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialNCT07820111DulaglutidePhase 3Completed1592025-10-18
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028Tirzepatide, RetatrutidePhase 3Recruiting45002025-10-15
A Phase 3 Study of HS-20094 in Patients With T2DMNCT07156539DulaglutidePhase 3Not yet recruiting5462025-09-30
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884OrforglipronPhase 3Recruiting10002025-09-30
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086CagrilintidePhase 1Active not recruiting802025-09-26
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)NCT07188545Dulaglutide, Exenatide—Active not recruiting232800002025-09-15
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471OrforglipronPhase 3Active not recruiting8002025-09-15
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusNCT07319286DulaglutidePhase 1/Phase 2Enrolling by invitation502025-08-04
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist TherapyNCT06903923LiraglutidePhase 2Recruiting1202025-07-31
Probiotics in Obese Patients Treated With SemaglutideNCT07847593Semaglutide—Completed1022025-07-09
GLP-1s to Enhance Lasting Optimal WeightNCT06861439TirzepatidePhase 4Active not recruiting402025-07-07
A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaNCT07064486SemaglutidePhase 3Active not recruiting1522025-07-04
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility StudyNCT06759701TirzepatideEARLY_Phase 1Recruiting302025-07-02
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086TirzepatidePhase 3Recruiting3502025-06-26
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099TirzepatidePhase 3Recruiting2902025-06-26
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisNCT07225829LiraglutidePhase 2Active not recruiting1292025-06-17
The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432CagrilintidePhase 1Recruiting1442025-06-12
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846RetatrutidePhase 1Completed802025-06-06
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667CagrilintidePhase 3Active not recruiting6092025-06-03
Semaglutide for Helping Opioid RecoveryNCT06639464SemaglutidePhase 2Recruiting462025-06-02
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859Semaglutide, RetatrutidePhase 1Active not recruiting952025-06-02
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093RetatrutidePhase 3Active not recruiting5862025-05-29
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.NCT06851962DulaglutidePhase 4Completed922025-05-26
Tirzepatide vs Liraglutide in BoneNCT07094568Liraglutide—Recruiting722025-05-23
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792OrforglipronPhase 3Active not recruiting14002025-05-15
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459OrforglipronPhase 3Active not recruiting8002025-05-15
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminNCT07109700DulaglutidePhase 2Recruiting2162025-04-30
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435OrforglipronPhase 3Active not recruiting4872025-04-30
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422OrforglipronPhase 3Active not recruiting9742025-04-30
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530OrforglipronPhase 3Active not recruiting4872025-04-30
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 DiabetesNCT06706284SemaglutidePhase 4Recruiting502025-04-11
A Study of BGM0504 in Participants With ObesityNCT06911203TirzepatidePhase 2Completed962025-04-09
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475Semaglutide, TirzepatidePhase 2Recruiting2002025-03-28
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin ResistanceNCT06856291Semaglutide—Completed402025-03-15
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268RetatrutidePhase 3Active not recruiting6432025-03-05
Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)NCT06854614TirzepatidePhase 4Active not recruiting1502025-03-01
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449CagrilintidePhase 3Active not recruiting4002025-02-10
Tirzepatide for Obesity and Meth Use DisorderNCT06745128TirzepatidePhase 2Completed352025-02-03
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802RetatrutidePhase 1Completed302025-02-03
Study of Patients Being Treated With Anti-obesity MedicationNCT06790160Semaglutide, Tirzepatide—Active not recruiting1002025-01-31
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869CagrilintidePhase 2Completed1422025-01-29
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122DulaglutidePhase 3Recruiting552025-01-10
Semaglutide in Women With Polycystic Ovary Syndrome and ObesityNCT06896981SemaglutidePhase 2/Phase 3Completed312025-01-01
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsNCT07325435Liraglutide, DulaglutidePhase 4Active not recruiting602024-12-21
Assessment of Safety, Tolerability and Drug Levels of Exenatide ImplantNCT05670379ExenatidePhase 1Completed242024-12-20
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538TirzepatidePhase 1/Phase 2Recruiting1802024-12-04
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.NCT06719011CagrilintidePhase 1Completed1782024-12-03
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307CagrilintidePhase 1Completed182024-12-02
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent ThalassemiaNCT07370922DulaglutidePhase 2Completed802024-11-22
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)NCT06191848TirzepatidePhase 4Active not recruiting3522024-11-19
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549OrforglipronPhase 3Recruiting1252024-11-18
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939OrforglipronPhase 3Recruiting1502024-11-18
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411CagrilintidePhase 3Completed10232024-11-05
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383RetatrutidePhase 3Active not recruiting8002024-11-01
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT06779929Dulaglutide—Completed700002024-11-01
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045OrforglipronPhase 3Completed7122024-10-22
Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.NCT06888167Exenatide—Recruiting402024-10-14
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective SurgeryNCT06500143Dulaglutide—Completed942024-10-09
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular RiskNCT07096063Dulaglutide—Completed8871322024-10-01
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims DataNCT07088718Dulaglutide—Completed446712024-10-01
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsNCT05663515Exenatide—Recruiting240002024-09-30
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571TirzepatidePhase 2Completed3672024-09-20
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916OrforglipronPhase 3Completed3762024-09-13
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectNCT06058585SemaglutidePhase 3Recruiting20002024-09-04
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in BangladeshNCT06449235ExenatidePhase 4Unknown9382024-09
Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908LiraglutidePhase 3Completed1832024-08-01
Exenatide For Reducing the Reinforcing Effects of CocaineNCT06252623ExenatidePhase 1Withdrawn02024-08-01
Holding vs. Continuing Incretin-based Therapies Before Upper EndoscopyNCT06533527DulaglutidePhase 4Completed692024-07-31
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminNCT06257966Dulaglutide, ExenatidePhase 3Active not recruiting6002024-07-17
Fibrosis Lessens After Metabolic SurgeryNCT06374875LiraglutidePhase 4Recruiting1202024-07-11
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM PatientsNCT06254014ExenatidePhase 3Active not recruiting2702024-07-10
Risk Factors Affect Weight Loss Outcomes After Treatment.NCT06482411Liraglutide—Completed36022024-06-27
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187CagrilintidePhase 3Completed3002024-06-24
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980OrforglipronPhase 1Completed5332024-06-24
The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical TrialNCT06050577SemaglutidePhase 2Active not recruiting642024-06-07
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277TirzepatidePhase 3Recruiting3002024-06-03
Diabetes Islet Preservation Immune TreatmentNCT02586831ExenatidePhase 1/Phase 2Withdrawn02024-06-01
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130CagrilintidePhase 2Completed2702024-05-20
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesNCT06403761CagrilintidePhase 1Completed1582024-05-06
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsNCT06370728OrforglipronPhase 1Completed302024-05-06
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390RetatrutidePhase 3Active not recruiting100002024-04-30
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660RetatrutidePhase 3Completed5372024-04-10
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.NCT06283641Liraglutide—Completed3002024-04-08
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusNCT06235086DulaglutidePhase 3Completed6322024-04-08
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372CagrilintidePhase 2Completed6262024-04-01
Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityNCT07590219LiraglutidePhase 4Active not recruiting302024-03-30
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161CagrilintidePhase 3Completed2742024-03-26
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528RetatrutidePhase 1Completed852024-03-20
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryNCT06324461DulaglutidePhase 4Recruiting3722024-03-20
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174CagrilintidePhase 3Completed1892024-03-19
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603RetatrutidePhase 3Active not recruiting3202024-03-15
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504CagrilintidePhase 1Completed342024-02-27
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877CagrilintidePhase 1Completed622024-02-23
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722RetatrutidePhase 3Active not recruiting12502024-02-21
A Study of How CagriSema Works on Appetite in People With Excess Body WeightNCT06267092CagrilintidePhase 1Completed1642024-02-15
A Study of HS-20094 in Patients With T2DMNCT06901648DulaglutidePhase 2Completed2752024-02-06
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory IssuesNCT06171152LiraglutideEARLY_Phase 1Suspended302024-01-26
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969CagrilintidePhase 3Completed10242024-01-16
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DMNCT06256419Exenatide—Recruiting3002024-01-01
Pharmacological Treatment - An Overview of Its Role in Managing Childhood ObesityNCT07304141Liraglutide—Completed1282023-12-20
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437CagrilintidePhase 3Completed8092023-11-27
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956TirzepatidePhase 2Recruiting14812023-11-17
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311OrforglipronPhase 3Completed5462023-11-10
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese SubjectsNCT06247748ExenatidePhase 1Completed282023-10-19
A Phase I Study of LY3502970 in Healthy ParticipantsNCT06085482OrforglipronPhase 1Completed102023-10-19
Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesNCT05478707DulaglutidePhase 2Recruiting472023-10-05
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004OrforglipronPhase 3Completed4012023-09-28
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540CagrilintidePhase 3Completed27342023-09-27
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221OrforglipronPhase 3Completed16982023-09-22
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related ComorbiditiesNCT06023095OrforglipronPhase 1Completed242023-09-21
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDNCT07309094Dulaglutide, Exenatide—Recruiting2502023-09-15
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826RetatrutidePhase 1Completed462023-09-12
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic SurgeryNCT07374445LiraglutidePhase 4Completed1002023-09-01
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465RetatrutidePhase 1Completed572023-08-29
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848CagrilintidePhase 3Completed3002023-08-15
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940OrforglipronPhase 3Completed5592023-08-09
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367RetatrutidePhase 3Completed4452023-08-01
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseNCT05931380OrforglipronPhase 3Completed2382023-07-31
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151RetatrutidePhase 2Completed1462023-07-20
A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096RetatrutidePhase 1Completed852023-07-18
A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560RetatrutidePhase 1Completed432023-07-13
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.NCT05936138OrforglipronPhase 1Completed242023-07-13
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079RetatrutidePhase 3Completed11522023-07-11
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066RetatrutidePhase 3Completed23352023-07-10
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightNCT05726227SemaglutidePhase 3Active not recruiting2122023-07-07
Preoperative Weight Loss for Open Abdominal Wall ReconstructionNCT05925959Liraglutide—Recruiting2582023-06-19
A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionNCT05882032OrforglipronPhase 1Completed292023-06-13
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620OrforglipronPhase 3Completed16132023-06-05
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903OrforglipronPhase 3Active not recruiting31272023-06-05
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045RetatrutidePhase 3Completed19462023-05-30
Effects of GH and Lirglutide on AgRPNCT05681299LiraglutidePhase 4Recruiting402023-05-01
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05841238OrforglipronPhase 1Completed522023-04-26
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational DiabetesNCT05482789ExenatidePhase 4Recruiting132023-04-12
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925CagrilintidePhase 3Completed3312023-04-03
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755CagrilintidePhase 3Active not recruiting71012023-03-01
Clinical Study of 18F-Exendin-4 in InsulinomaNCT07340437Exenatide—Completed202023-02-01
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519CagrilintidePhase 3Completed12002023-02-01
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaNCT05579249LiraglutidePhase 4Completed5002023-01-19
Exenatide for Smoking Cessation and Prevention of Weight GainNCT05610800ExenatidePhase 2Completed1402022-12-07
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)NCT05564039DulaglutidePhase 4Completed2822022-11-30
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957RetatrutidePhase 1Completed292022-11-16
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796CagrilintidePhase 3Active not recruiting34002022-11-01
Semaglutide vs SitagliptinNCT05195944SemaglutidePhase 4Active not recruiting582022-10-26
A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231RetatrutidePhase 1Completed322022-10-24
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512TirzepatidePhase 3Active not recruiting153742022-10-11
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529Liraglutide—Completed3962022-10-08
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesNCT05390892Liraglutide, DulaglutidePhase 4Recruiting60002022-09-26
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy ParticipantsNCT05469126OrforglipronPhase 1Completed262022-08-01
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232RetatrutidePhase 1Completed322022-07-08
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)NCT05356104ExenatidePhase 2Recruiting1102022-05-25
A Study of Two Different Formulations of LY3502970 in Healthy ParticipantsNCT05341089OrforglipronPhase 1Completed392022-05-17
Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes MellitusNCT05662189Exenatide—Recruiting702022-03-15
Adiponectin in Patients With Metabolic DisordersNCT07539584Liraglutide—Completed1302022-03-01
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 DiabetesNCT04307797ExenatidePhase 4Completed102022-01-18
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes MellitusNCT05086445OrforglipronPhase 1Completed622021-11-12
A Multiple Dose Study of LY3502970 in Healthy ParticipantsNCT05051566OrforglipronPhase 1Completed262021-09-16
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)NCT04897802ExenatidePhase 4Completed422021-09-13
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917Liraglutide, Dulaglutide, Exenatide—Active not recruiting7814302021-08-01
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceNCT04731272DulaglutidePhase 2Recruiting302021-07-16
Comparison of Type 2 Diabetes Pharmacotherapy RegimensNCT05073692Exenatide—Completed2419812021-07-01
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)NCT04823208RetatrutidePhase 1Completed642021-05-24
A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760RetatrutidePhase 2Completed3382021-05-20
A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785RetatrutidePhase 2Completed2812021-05-13
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)NCT04822181SemaglutidePhase 3Active not recruiting12052021-04-01
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityNCT04775082LiraglutidePhase 3Active not recruiting782021-03-04
Brain Activation and Satiety in Children 2NCT04520490ExenatidePhase 3Active not recruiting632021-01-28
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic SyndromeNCT04575844LiraglutidePhase 4Recruiting802020-11-01
Exenatide Once-weekly as a Treatment for Multiple System AtrophyNCT04431713ExenatidePhase 2Completed502020-09-16
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433DulaglutidePhase 3Completed132992020-05-29
A Clinical Study of NLY01 in Patient's With Early Parkinson's DiseaseNCT04154072ExenatidePhase 2Completed2552020-02-27
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseNCT04232969ExenatidePhase 3Completed1942020-01-20
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802RetatrutidePhase 1Completed722019-12-18
A Study of LY3502970 in Healthy ParticipantsNCT03929744OrforglipronPhase 1Completed1332019-06-12
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesNCT03811561SemaglutidePhase 3Active not recruiting15002019-05-08
Liraglutide Effect in Atrial FibrillationNCT03856632LiraglutidePhase 4Active not recruiting602019-03-18
A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsNCT03841630RetatrutidePhase 1Completed452019-03-13
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)NCT03883412LiraglutidePhase 4Recruiting602019-02-28
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related DiseaseNCT06725693Exenatide—Recruiting5002019-02-01
Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance ImagingNCT03498001Liraglutide, Dulaglutide—Completed422018-04-16
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular DiseaseNCT03492580Dulaglutide, Exenatide—Completed7145822018-02-22
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their CombinationNCT03878706Liraglutide, MOTS-c—Recruiting2402017-11-03
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyNCT02860923ExenatidePhase 3Completed422017-01-11
Saxenda: Underlying Mechanisms and Clinical OutcomesNCT02944500LiraglutidePhase 4Active not recruiting282016-11
Pharmacogenomics of GLP1 Receptor AgonistsNCT05762744ExenatidePhase 1Terminated632016-06-01
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican PatientsNCT02773355Liraglutide—Completed272016-05-16
GLP-1 and Hyperoxia for Organ Protection in Heart SurgeryNCT02673931Exenatide—Unknown14002016-02
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal SyndromeNCT02251431ExenatidePhase 3Completed572015-11
Liver and Fat Regulation in Overweight Adolescent GirlsNCT02157974ExenatidePhase 2/Phase 3Completed922014-08
Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 DiabetesNCT02674893LiraglutidePhase 4Terminated482014-02-04
GLP-1's Effect on Cardiac Parameters and Mesenteric Blood FlowNCT01988545Exenatide—Completed82013-11-01
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesNCT01794143LiraglutidePhase 3Completed78502013-05
Effect of Liraglutide on Fatty Liver Content and Lipoprotein MetabolismNCT02721888LiraglutidePhase 4Terminated1272012-07-10
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese DiabeticsNCT02042664ExenatidePhase 3Completed442011-01
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DMNCT01107717ExenatidePhase 4Completed3182009-01
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) ProtocolNCT00679042ExenatidePhase 3Active not recruiting212007-09-05
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial EmulationNCT07677865Liraglutide—Completed2138912007-01-01
Pre-approval Expanded Access of Retatrutide (LY3437943)NCT07629401Retatrutide—Available——

Citation: Synptide GLP-1 Clinical Trials, v1.0(synptide.com/datasets), sourced from ClinicalTrials.gov (public domain). The Synptide compound tagging is licensed CC BY 4.0. Registry data can lag real-world status — confirm on the source record before relying on it.